Incyte Corp. and Merck said an external Data Monitoring Committee review of the pivotal phase III ECHO-301/KEYNOTE-252 study results evaluating Incyte’s epacadostat in combination with Merck’s Keytruda in patients with unresectable or metastatic melanoma determined that the study did not meet the primary endpoint of improving progression-free survival in the overall population compared to Keytruda monotherapy.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
